Study wrapper · #884
Incretin-Based Therapies in Doxorubicin-Induced Cardiotoxicity: A Systematic Review of GLP-1 and Dual GIP/GLP-1 Agonists.
Khatami S, Faghihi M, Tavakoli G, et al. Cardiovascular toxicology. 2026.
DOI: 10.1007/s12012-026-10119-6PubMed: 42455418
Editor's note
This review pools thirteen small rodent studies and reports incretin therapies were associated with better left ventricular function during doxorubicin exposure. Semaglutide and tirzepatide each appear in only a handful of animal studies, and the authors rate certainty as low-to-very-low. Findings are explicitly hypothesis-generating with no human data, so weight is limited.
Plain-language abstract
A systematic review of rodent studies found that incretin-based drugs, including semaglutide and tirzepatide, were associated with preserved heart function during doxorubicin chemotherapy, though no human studies existed.
Related coverage
Mixed
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.
International journal of qualitative studies on health and well-beingn=——2026
Weak / none
Design, synthesis, and stability evaluation of semaglutide-derived lactam-stapled peptide scaffolds for GLP-1R targeting.
Journal of enzyme inhibition and medicinal chemistryn=——2026
Mixed
Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.
Journal of obstetrics and gynaecologyn=——2026